ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

ImmunoGen Inc. (Nasdaq: IMGN) announced on January 31, 2022, that its Board of Directors granted stock options to purchase 525,600 shares to four new employees under its Inducement Equity Incentive Plan. The options, priced at $5.65 per share, will vest over four years, incentivizing new hires. This plan is designed for individuals not previously employed by ImmunoGen, aligning with Nasdaq Listing Rule 5635(c)(4). ImmunoGen focuses on developing innovative antibody-drug conjugates aimed at improving cancer treatment outcomes.

Positive

• Granting of stock options to new employees can enhance talent acquisition and retention.
• The exercise price of $5.65 aligns with the current market value, promoting investor confidence.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 31, 2022, the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 525,600 shares of its common stock to four new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employees’ becoming employees of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $5.65 per share, which is equal to the closing price of ImmunoGen’s common stock on the Nasdaq Global Select Market on January 31, 2022. Each option will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to such employee’s continued employment with ImmunoGen on such vesting dates. Each option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005468/en/

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

What is the stock option grant announced by ImmunoGen on January 31, 2022?

ImmunoGen granted stock options to purchase 525,600 shares to four new employees under its Inducement Equity Incentive Plan.

What was the exercise price for the stock options granted by ImmunoGen?

The exercise price for the stock options was $5.65 per share.

How long is the vesting period for the stock options granted by ImmunoGen?

The stock options will vest over a four-year period.

What is the purpose of the Inducement Equity Incentive Plan at ImmunoGen?

The plan is intended to attract new employees who were not previously employed by ImmunoGen.

What are antibody-drug conjugates and why are they important for ImmunoGen?

Antibody-drug conjugates are targeted cancer therapies that improve treatment outcomes and tolerability for patients.